These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment. Jensen RH Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of fungal resistance: an overview. Balkis MM; Leidich SD; Mukherjee PK; Ghannoum MA Drugs; 2002; 62(7):1025-40. PubMed ID: 11985489 [TBL] [Abstract][Full Text] [Related]
4. Antifungal drug resistance in pathogenic fungi. Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500 [TBL] [Abstract][Full Text] [Related]
5. The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies. Reales-Calderón JA; Molero G; Gil C; Martínez JL Future Med Chem; 2016 Aug; 8(12):1503-20. PubMed ID: 27485839 [TBL] [Abstract][Full Text] [Related]
6. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. White TC; Marr KA; Bowden RA Clin Microbiol Rev; 1998 Apr; 11(2):382-402. PubMed ID: 9564569 [TBL] [Abstract][Full Text] [Related]
7. Heteroresistance and fungi. Ferreira GF; Santos DA Mycoses; 2017 Sep; 60(9):562-568. PubMed ID: 28660647 [TBL] [Abstract][Full Text] [Related]
8. Fungal Biofilms: Update on Resistance. Borghi E; Borgo F; Morace G Adv Exp Med Biol; 2016; 931():37-47. PubMed ID: 27115411 [TBL] [Abstract][Full Text] [Related]
12. Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help? Hull CM; Purdy NJ; Moody SC Future Microbiol; 2014; 9(3):307-25. PubMed ID: 24762306 [TBL] [Abstract][Full Text] [Related]
13. Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi. Hokken MWJ; Zwaan BJ; Melchers WJG; Verweij PE Fungal Genet Biol; 2019 Nov; 132():103254. PubMed ID: 31326470 [TBL] [Abstract][Full Text] [Related]
14. Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. Bastert J; Schaller M; Korting HC; Evans EG Int J Antimicrob Agents; 2001 Feb; 17(2):81-91. PubMed ID: 11165110 [TBL] [Abstract][Full Text] [Related]
15. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Delarze E; Sanglard D Drug Resist Updat; 2015 Nov; 23():12-19. PubMed ID: 26690338 [TBL] [Abstract][Full Text] [Related]
16. [Current status of studies on sensitivity to antifungal agents]. Martín Mazuelos E Enferm Infecc Microbiol Clin; 1992; 10(6):366-71. PubMed ID: 1391021 [No Abstract] [Full Text] [Related]
17. Medically important fungi respond to azole drugs: an update. Zavrel M; White TC Future Microbiol; 2015; 10(8):1355-73. PubMed ID: 26234644 [TBL] [Abstract][Full Text] [Related]
19. Clinical utility of in vitro antifungal susceptibility testing. Espinel-Ingroff A Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088 [TBL] [Abstract][Full Text] [Related]
20. Mathematical modeling of fungal infection in immune compromised individuals: The effect of back mutation on drug treatment. Wirkus S; Camacho ET; Marshall PA J Theor Biol; 2015 Nov; 385():66-76. PubMed ID: 26341388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]